Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1985 Apr;82(8):2498–2502. doi: 10.1073/pnas.82.8.2498

Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.

A V Schally, T W Redding
PMCID: PMC397586  PMID: 3157990

Abstract

The effect of combining hormonal treatment consisting of long-acting microcapsules of the agonist [D-Trp6]LH-RH (the D-tryptophan-6 analog of luteinizing hormone-releasing hormone) with the chemotherapeutic agent cyclophosphamide was investigated in the Dunning R-3327H rat prostate cancer model. Microcapsules of [D-Trp6]LH-RH formulated from poly(DL-lactide-co-glycolide) and calculated to release a controlled dose of 25 micrograms/day were injected intramuscularly once a month. Cyclophosphamide (Cytoxan) (5 mg/kg of body weight) was injected intraperitoneally twice a week. When the therapy was started 90 days after tumor transplantation--at the time that the cancers were well developed-and was continued for 2 months, tumor volume was significantly reduced by the microcapsules or Cytoxan given alone. The combination of these two agents similarly inhibited tumor growth but did not show a synergistic effect. In another study, the treatment was started 2 months after transplantation, when the developing tumors measured 60-70 mm3. Throughout the treatment period of 100 days, the microcapsules of [D-Trp6]LH-RH reduced tumor volume more than Cytoxan did, and the combination of the two drugs appeared to completely arrest tumor growth. Tumor weights also were diminished significantly in all experimental groups, the decrease in weight being smaller in the Cytoxan-treated group than in rats that received the microcapsules. The combination of Cytoxan plus the microcapsules was 10-100 times more effective than the single agents in reducing tumor weights. In both experiments, testes and ventral prostate weights were significantly diminished, serum testosterone was suppressed to undetectable levels, and prolactin values were reduced by administration of microcapsules of [D-Trp6]LH-RH alone or in combination with Cytoxan. These results in rats suggest that combined administration of long acting microcapsules of [D-Trp6]LH-RH with a chemotherapeutic agent, started soon after the diagnosis of prostate cancer is made, might inhibit the proliferation of androgen-dependent and -independent cells, improve further the therapeutic response, and increase the survival rate.

Full text

PDF
2498

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmed S. R., Brooman P. J., Shalet S. M., Howell A., Blacklock N. J., Rickards D. Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms. Lancet. 1983 Aug 20;2(8347):415–419. doi: 10.1016/s0140-6736(83)90387-2. [DOI] [PubMed] [Google Scholar]
  2. Allen J. M., O'Shea J. P., Mashiter K., Williams G., Bloom S. R. Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist. Br Med J (Clin Res Ed) 1983 May 21;286(6378):1607–1609. doi: 10.1136/bmj.286.6378.1607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Asch R. H., Rojas F. J., Bartke A., Schally A. V., Tice T. R., Klemcke H. G., Siler-Khodr T. M., Bray R. E., Hogan M. P. Prolonged suppression of plasma LH levels in male rats after a single injection of an LH-RH agonist in poly(DL-lactide-co-glycolide) microcapsules. J Androl. 1985 Mar-Apr;6(2):83–88. doi: 10.1002/j.1939-4640.1985.tb00821.x. [DOI] [PubMed] [Google Scholar]
  4. Borgmann V., Nagel R., Al-Abadi H., Schmidt-Gollwitzer M. Treatment of prostatic cancer with LH-RH analogues. Prostate. 1983;4(6):553–568. doi: 10.1002/pros.2990040603. [DOI] [PubMed] [Google Scholar]
  5. Comaru-Schally A. M., Ramalho A., Leitao P. R., Schally A. V. Clearance of lung metastases of prostate carcinoma after treatment with LH-RH agonist. Lancet. 1984 Aug 4;2(8397):281–282. doi: 10.1016/s0140-6736(84)90319-2. [DOI] [PubMed] [Google Scholar]
  6. Geller J., Albert J. D. Comparison of various hormonal therapies for prostatic carcinoma. Semin Oncol. 1983 Dec;10(4 Suppl 4):34–41. [PubMed] [Google Scholar]
  7. Isaacs J. T., Coffey D. S. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res. 1981 Dec;41(12 Pt 1):5070–5075. [PubMed] [Google Scholar]
  8. Isaacs J. T. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate. 1984;5(1):1–17. doi: 10.1002/pros.2990050102. [DOI] [PubMed] [Google Scholar]
  9. Janik P., Briand P., Hartmann N. R. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res. 1975 Dec;35(12):3698–3704. [PubMed] [Google Scholar]
  10. Könyves I., Müntzing J., Rozencweig M. Chemotherapy principles in the treatment of prostatic cancer. Prostate. 1984;5(1):55–62. doi: 10.1002/pros.2990050106. [DOI] [PubMed] [Google Scholar]
  11. Labrie F., Dupont A., Belanger A., Lacoursiere Y., Raynaud J. P., Husson J. M., Gareau J., Fazekas A. T., Sandow J., Monfette G. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate. 1983;4(6):579–594. doi: 10.1002/pros.2990040605. [DOI] [PubMed] [Google Scholar]
  12. Mason-Garcia M., Vigh S., Comaru-Schally A. M., Redding T. W., Somogyvari-Vigh A., Horvath J., Schally A. V. Radioimmunoassay for 6-D-tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long-acting microcapsule formulations. Proc Natl Acad Sci U S A. 1985 Mar;82(5):1547–1551. doi: 10.1073/pnas.82.5.1547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mathé G., Vo Van M. L., Duchier J., Misset J. L., Morin P., Keiling R., Schwarzenberg L., Kerbrat P., Achille E., Tronc J. C. An oriented phase-II trial of D-Trp6-LH-RH in patients with prostatic carcinoma. Med Oncol Tumor Pharmacother. 1984;1(2):119–122. doi: 10.1007/BF02934983. [DOI] [PubMed] [Google Scholar]
  14. Mukamel E., Nissenkorn I., Servadio C. Early combined hormonal and chemotherapy for metastatic carcinoma of prostate. Urology. 1980 Sep;16(3):257–260. doi: 10.1016/0090-4295(80)90037-0. [DOI] [PubMed] [Google Scholar]
  15. Murphy G. P., Beckley S., Brady M. F., Chu T. M., deKernion J. B., Dhabuwala C., Gaeta J. F., Gibbons R. P., Loening S. A., McKiel C. F. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer. 1983 Apr 1;51(7):1264–1272. doi: 10.1002/1097-0142(19830401)51:7<1264::aid-cncr2820510716>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  16. Plotka E. D., Seal U. S., Letellier M. A., Verme L. J., Ozoga J. J. Early effects of pinealectomy on LH and testosterone secretion in white-tailed deer. J Endocrinol. 1984 Oct;103(1):1–7. doi: 10.1677/joe.0.1030001. [DOI] [PubMed] [Google Scholar]
  17. Redding T. W., Schally A. V. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A. 1981 Oct;78(10):6509–6512. doi: 10.1073/pnas.78.10.6509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Redding T. W., Schally A. V., Tice T. R., Meyers W. E. Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules. Proc Natl Acad Sci U S A. 1984 Sep;81(18):5845–5848. doi: 10.1073/pnas.81.18.5845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Schally A. V., Comaru-Schally A. M., Redding T. W. Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc Soc Exp Biol Med. 1984 Mar;175(3):259–281. doi: 10.3181/00379727-175-41797. [DOI] [PubMed] [Google Scholar]
  20. Schally A. V., Redding T. W., Comaru-Schally A. M. Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH. Prostate. 1983;4(6):545–552. doi: 10.1002/pros.2990040602. [DOI] [PubMed] [Google Scholar]
  21. Schmidt J. D., Scott W. W., Gibbons R., Johnson D. E., Prout G. R., Jr, Loening S., Soloway M., deKernion J. B., Pontes J. E., Slack N. H. Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer. 1980 Apr 15;45(7 Suppl):1937–1946. [PubMed] [Google Scholar]
  22. Smith I. E., Stuart-Harris R., Pavlidis N., Bozek T. Mitoxantrone (Novantrone) as single agent and in combination chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rev. 1983 Dec;10 (Suppl B):37–40. doi: 10.1016/0305-7372(83)90020-8. [DOI] [PubMed] [Google Scholar]
  23. Tolis G., Ackman D., Stellos A., Mehta A., Labrie F., Fazekas A. T., Comaru-Schally A. M., Schally A. V. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A. 1982 Mar;79(5):1658–1662. doi: 10.1073/pnas.79.5.1658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Torti F. M., Carter S. K. The chemotherapy of prostatic adenocarcinoma. Ann Intern Med. 1980 May;92(5):681–689. doi: 10.7326/0003-4819-92-5-681. [DOI] [PubMed] [Google Scholar]
  25. Walker K. J., Nicholson R. I., Turkes A. O., Turkes A., Griffiths K., Robinson M., Crispin Z., Dris S. Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma. Lancet. 1983 Aug 20;2(8347):413–415. doi: 10.1016/s0140-6736(83)90386-0. [DOI] [PubMed] [Google Scholar]
  26. Warner B., Worgul T. J., Drago J., Demers L., Dufau M., Max D., Santen R. J. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer. J Clin Invest. 1983 Jun;71(6):1842–1853. doi: 10.1172/JCI110940. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Waxman J. H., Wass J. A., Hendry W. F., Whitfield H. N., Besser G. M., Malpas J. S., Oliver R. T. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. Br Med J (Clin Res Ed) 1983 Apr 23;286(6374):1309–1312. doi: 10.1136/bmj.286.6374.1309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Yagoda A. Proceedings: Non-hormonal cytotoxic agents in the treatment of prostatic adenocarcinoma. Cancer. 1973 Nov;32(5):1131–1140. doi: 10.1002/1097-0142(197311)32:5<1131::aid-cncr2820320519>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES